Report: Generic Strategies in Emerging Markets TOC

Key findings
Overview of generics in emerging markets
- Emerging markets offer the greatest opportunity for growth despite some obstacles
- Branded Pharma' s drive into the emerging markets
Drivers and resistors of the generics markets of Latin America and Central and Eastern Europe
- Drivers and resistors for multinational entry in the CEE generics markets
- Drivers and resistors of the Latin American generics markets
- Generics penetration in the emerging markets is higher than in the mature and immature generics markets
Recent regulatory changes in key Latin American countries
- IP laws in Latin America must be strengthened to attract foreign companies
- Regulatory changes are creating fertile ground for the generics industry
- Emergence of pharmacy chains in Latin America promotes generics use
Recent regulatory changes in key Central and Eastern European countries
- IP laws in CEE are being aligned with the rest of Europe
- Generics are often priced based on a referencing system
- Generic regulatory changes will affect foreign generic companies in Romania but boost the generic segment in Poland and the Czech Republic
- There could be a shortage of drugs in Polish pharmacies if companies fail to re-register medicines

Key findings
Comparative overview of Central and Eastern European and Latin American generics company strategies
- Differences between generics company strategies in CEE and Latin America
- Big Pharma strategies for accessing the emerging markets
- Multinational generics company strategies for accessing the emerging markets
Analysis of the key domestic and international generics companies in Central and Eastern Europe
- Domestic generic companies in CEE
- International generic companies in the CEE
Analysis of the key domestic and international generics companies in Latin America
- Domestic generic companies in Latin America
- International generic companies in Latin America

Table: Average size and growth rates for domestic and multinational generic companies in Central and Eastern Europe, 2004 - 08
Table: Average size and growth rates for domestic and multinational generic companies in Latin America, 2004 - 08
Table: Annual growth (%) for the top Indian generic companies in Central and Eastern Europe and Latin America, 2007 - 08
Table: Actavis' s acquisitions reflect a strategy to broaden and deepen its presence in the generics sector, 2004 - 08

Figure: Geographical split of the global generics market, 2009
Figure: The global generics continuum
Figure: The emerging markets for generics are proving especially attractive
Figure: Global pharmaceutical sales, 2007 - 2012
Figure: Drivers and resistors for multinationals entering Latin America or Central and Eastern Europe
Figure: Central and Eastern Europe has the highest generic penetration, 2008
Figure: Market share of generics and generics sales in Central and Eastern Europe versus other European countries, 2007
Figure: The varying levels of generic penetration in Latin American countries, 2007 - 08
Figure: Multinational versus domestic growth rates by volume and value in Central and Eastern Europe, 2004 - 08
Figure: Multinational versus domestic growth rates by volume and value in Latin America, 2004 - 08
Figure: Domestic generic companies in Central and Eastern Europe by volume and value, 2004 - 08
Figure: International generic companies in Central and Eastern Europe by volume and value, 2004 - 08
Figure: Domestic generic companies in Latin America by volume and value, 2004 - 08
Figure: Medley provides significant diversification of Sanofi-Aventis' s Brazilian portfolio, 2008
Figure: International generic companies in Latin America by volume and value, 2004 - 08
Figure: Glenmark has reorganized into two separate business units with a different strategic focus

Generic Strategies in Emerging Markets